Reply  by Hiro, Takafumi et al.
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eply
irst, we express our deep appreciation for the sincere criticism by
r. Kaneda and colleagues of our paper (1). However, we have a
ew concerns regarding their arguments.
. The REVERSAL (REVERSing Atherosclerosis with Aggressive
Lipid Lowering) study (2) examined patients with stable coronary
artery disease who could undergo an elective cardiac catheteriza-
tion, whereas the PROVE-IT–TIMI 22 (Pravastatin or Atorva-
statin Evaluation and Infection Therapy–Thrombolysis In Myo-
cardial Infarction 22) (3) and our JAPAN-ACS (Japan
Assessment of Pitavastatin and Atorvastatin in Acute Coronary
Syndrome) study examined patients with acute coronary syn-
drome. Several reports have been published that nonculprit plaque
differs in tissue characteristics between acute coronary syndrome
and stable coronary artery disease. Therefore, extrapolations of the
data between the REVERSAL and the PROVE-IT–TIMI 22
studies have major limitations.
. Their criticism was not based on any kind of rational statistical
meta-analysis. The value of the difference in the mean percent-
age of change in plaque volume of 1.3% in the REVERSAL
study cannot necessarily be considered similar to the 1.1% in
our study. The value of 1.3% of the REVERSAL study came
from the difference between 5.4% and 4.1%, whereas the value
of 1.1% in our study resulted from the difference between
16.9% and 18.1%. Therefore, 1.3% of the REVERSAL
study might be considerably more remarkable than 1.1% in our
study.
. The intravenous ultrasound measurement of plaque volume
differed between the REVERSAL study and our study. The
REVERSAL study measured the longer segment with a total
of 30 mm or more integrated with 1-mm interval cross-
sectional area tracings, whereas our study measured a specific
plaque segment of a total length of approximately 7 mm with
0.1-mm interval tracings. Therefore, even a similar differ-
ence in the mean percentage of change in plaque volume in
the REVERSAL study might have a more significant clinical
impact on future cardiac events than that in our study.
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he BALANCE Study
oo Early to Speculate
n Mortality Effects
e read with great interest the paper by Yousef et al. (1) and the
ccompanying editorial (2) demonstrating and discussing long-
erm data on cardiac function and mortality in patients treated
ith autologous bone marrow cell (BMC) transplantation after
yocardial infarction.
We do not agree with the editorial’s statement that, based on
he new data, BMC infusion “can now be considered safe and
odestly efficacious” (2), despite the finding that fatal events were
ore frequent in the control group. The patient cohort studied and
he event rate observed were far too small to draw such conclu-
ions. The total number of fatal events was only 8. Also, if the
uthors had included hospitalizations in the analyses, as is often
one in outcome studies, such a combined end point would not
ave provided conclusive results. Of note, taking the results from
able 1 of their paper (1), there were 9 unplanned hospitalizations
n the BMC group and 8 in the intervention group.
In addition, a recent 4-year follow-up study with 86 patients,
espite slight improvements in cardiac function, could not identify
ignificant differences in myocardial viability or mortality (3). The
ALANCE (Clinical Benefit and Long-Term Outcome After In-
racoronary Autologous Bone Marrow Cell Transplantation in Pa-
ients With Acute Myocardial Infarction) trial thus may be viewed as
successful proof-of-principle study, but there still is a need for
arge-scale, placebo-controlled, double-blind clinical end point studies
o justify any conclusion with regard to safety or even mortality.
ortunately, such large trials are currently underway at several places
orldwide and will clarify those important outstanding issues.
Furthermore, the authors addressed paracrine effects of trans-
lanted autologous cells as the major mechanism explaining the
eneficial effects of BMC transplantation. In our view, additional
echanisms should be taken into account. BMC transplantation
